An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project ProCAncer-I project after three years of implementation ProCAncer-I’s vision is to deliver a platform featuring a unique collection of PCa mpMRI images worldwide, in terms of data quantity,...
By Prof. Kai Vilanova. Chief MRI Department. Institute of Biomedical Research of Girona (IDIBGI) Clinical Challenge: Can artificial intelligence based mpMRI with clinical data predict prostate cancer recurrence after prostatectomy? Radical prostatectomy (RP) is a...
By Sara Colantonio, Researcher at ISTI-CNR AI trustworthiness in prostate cancer: where we stand Artificial intelligence (AI) is set to drive groundbreaking medical solutions and services that could transform the diagnosis and treatment in clinical pracise, with...
Interview with Dr. Giacomo Aringhieri, Radiology Research Fellow, Academic Radiology, Department of Translational Research, University of Pisa What is the experience of a young researcher in participating in a European project with great impact on healthcare like...
Partner presentation: Candiolo Cancer Institute, FPO – IRCCS The Candiolo Cancer Institute mission is to give significant contribution to fight cancer, by understanding the basics and providing state-of-the-art diagnostic and therapeutic services. The Institute works...
Partner presentation: CNR – National Research Council of Italy (CNR-ISTI and CNR-IFAC) The National Research Council (CNR) is the main public research organisation in Italy with the aim of carrying out, promoting, disseminating, transferring and improving research...
Newsletter #6 Contents
An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging...
Prostate cancer is the second most commonly diagnosed cancer in men. Conventional screening relies on prostate specific antigen (PSA) levels in the blood, which can indicate prostate abnormalities but lacks specificity. Clinical examination and ultrasound also have...
The ProCAncer-I project aims to revolutionize prostate cancer diagnosis and treatment through the power of artificial intelligence and advanced imaging. By creating a large, federated database of prostate MRI scans and clinical data, the project enables the...
ProCAncer-I results | Prof. Daniele Regge on clinical validation In this video, we present the results of the clinical validation of AI models that were developed during the ProCAncer-i Project. Clinical validation is a critical step to ensure that AI tools not only...